NEULAND LABORATORIES
Back to Balance Sheet
|
NEULAND LABORATORIES Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹710 Cr | ₹466 Cr | ₹428 Cr | ₹439 Cr | ₹363 Cr |
What is the latest Total Current Liabilities ratio of NEULAND LABORATORIES ?
| Year | Total Current Liabilities |
|---|---|
| Mar2026 | ₹710 Cr |
| Mar2025 | ₹466 Cr |
| Mar2024 | ₹428 Cr |
| Mar2023 | ₹439 Cr |
| Mar2022 | ₹363 Cr |
How is Total Current Liabilities of NEULAND LABORATORIES Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹710 Cr | 52.51 | |
| Mar2025 | ₹466 Cr | 8.89 | |
| Mar2024 | ₹428 Cr | -2.57 | |
| Mar2023 | ₹439 Cr | 20.87 | |
| Mar2022 | ₹363 Cr | - | |
Compare Total Current Liabilities of peers of NEULAND LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NEULAND LABORATORIES | ₹29,355.8 Cr | 1.3% | 20.9% | 69.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹469,310.0 Cr | 0.5% | -4% | 15.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹245,426.0 Cr | 9.1% | 18.2% | 47.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹189,347.0 Cr | 3.6% | 3.4% | 36.4% | Stock Analytics | |
| CIPLA | ₹114,393.0 Cr | -1.2% | -3.3% | -10.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,240.2 Cr | -1.4% | 2.9% | -8% | Stock Analytics | |
NEULAND LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NEULAND LABORATORIES | 1.3% |
20.9% |
69.4% |
| SENSEX | -0.5% |
-1.3% |
-5.4% |
You may also like the below Video Courses